[go: up one dir, main page]

WO2002017947A2 - Utilisation de proteines t pour une caracterisation et une therapie differentielles de lesions et de tumeurs du systeme nerveux - Google Patents

Utilisation de proteines t pour une caracterisation et une therapie differentielles de lesions et de tumeurs du systeme nerveux Download PDF

Info

Publication number
WO2002017947A2
WO2002017947A2 PCT/DE2001/003392 DE0103392W WO0217947A2 WO 2002017947 A2 WO2002017947 A2 WO 2002017947A2 DE 0103392 W DE0103392 W DE 0103392W WO 0217947 A2 WO0217947 A2 WO 0217947A2
Authority
WO
WIPO (PCT)
Prior art keywords
protein
dna sequence
gene
tumors
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2001/003392
Other languages
German (de)
English (en)
Other versions
WO2002017947A3 (fr
Inventor
Annemarie Poustka
Johannes Coy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of WO2002017947A2 publication Critical patent/WO2002017947A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002017947A3 publication Critical patent/WO2002017947A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates to the use of T proteins or the nucleic acid sequences coding therefor and antibodies to the T proteins for the differential characterization and therapy of injuries and tumors of the nervous system.
  • the object of the present invention is therefore to provide diagnostic and therapeutic agents which make it possible to identify and treat the different molecular changes in different tumors and injuries to the nervous system. This is supposed to be a differential diagnosis and therapy of injuries and tumors of the nervous system be made possible.
  • the present invention relates to the use of at least one DNA sequence for the differential identification and therapy of molecular changes in injuries and tumors of the nervous system, the DNA sequence comprising the following DNA sequences:
  • FIGS. 1 to 3 are fragments or variants of the T genes (T1, T2, T3) which are described in detail in the earlier applications DE 199 08 423.8 and PCT / DE00 / 00583.
  • the T1 protein after an injury to the brain, is increasingly formed in the cells - mainly astrocytes - that surround the scar. No increased expression is found in the neurons and glial cells in the zone of anterograde degeneration in the early phase of degeneration.
  • the central nervous system responds to injuries and illnesses through strong proliferation of astrocytes, which leads to the formation of a neural / glial scar.
  • This process is subject to precise control mechanisms, since a CNS injury does not lead to an uncontrolled proliferation of astrocytes, as is the case with glial tumors, for example. Errors in regenerative processes after an injury to the nervous system or disturbances in the control of these processes can lead to tumor diseases of the nervous system.
  • the inventors therefore developed the control mechanisms and those involved Proteins identified. Through the targeted characterization and influencing of these mechanisms and proteins, a positive influence on healing processes of the nervous system and the therapy of tumors of the nervous system can be achieved.
  • Differentially spliced exons identified by the underlines in the sequences of FIGS. 1, 2 and 3 were identified by the inventors. These represent the decisive identification parameters for the classification of the various injuries and tumors of the nervous system. The existence or absence of the necessary conclusions can be drawn about the disease. With the help of these differentially spliced exons, it is possible to identify proteins or other molecules that interact with these sequences. These in turn can be used for the diagnosis and therapy of injuries and tumors of the nervous system as well as the sequences of Figures 1, 2 or 3 identified above.
  • genes T1, T2 and T3 are differentially expressed in tumors of the nervous system.
  • the genes T1 and T2 are expressed in the glioblastoma cell lines H4 and A172, whereas the expression of T3 is absent. All members of the T gene family are expressed in the four of seven glioblastoma cell lines tested (U118MG, U373-MG, U87MG and HS683). No expression of the T gene family was detectable in the U343MG glioblastoma cell line.
  • the medulloblastoma cellemia DAOY showed a reduced T1 and T2 expression while the T3 expression was missing. No expression of the T gene family could be detected in the leukemia cell line.
  • T3 In the primitive neuroectodermal tumor cell line MHH-PNET there is only expression of the T3 gene. This analysis shows that the three T genes are differentially expressed in tumor cell lines. Furthermore, analysis of the expression of T1 in primary tumors shows that expression in neuroblastomas is reduced. In 4 out of 10 neuroblastomas tested (NB-T3, NB-T4m, NB-T7, NB-T8) a reduced or almost absent expression of T1 was found. The extent of the reduction in expression is much stronger, since the tumors have a normal tissue proportion (approx. 20-50%). In primary neuroblastomas, the malignant phenotype is associated with a reduced expression of T1. These results are confirmed in Fig. 4.
  • the T1, T2 and T3 genes are regulated at the transcriptional level. A further complexity of the regulation of these genes could be shown, since multiple splice variants of the T genes could be isolated.
  • the exons marked with underlines in FIGS. 1, 2 and 3 could be identified. The size of two of these alternatively spliced exons is 42 and 24 bp.
  • the third differential exon has a different size within the T gene family. In T1, the third differentially spliced exon is 21 bp, while in T2 and T3 it is only 9 bp long. Differential splicing of these three exons results in eight different protein isoforms, 24 different protein isoforms within the T gene family, and 512 protein isoform combinations in total.
  • All three differentially spliced exons are located in an area flanked by the leucine zipper and the PXXP motif at T1.
  • Leucine zippers and PXXP motifs are well-studied protein motifs that enable protein-protein binding.
  • the three differentially spliced exons are located exactly in this area and specifically change the interaction of the T proteins with other proteins.
  • variants or “fragment” used in the present invention encompass DNA sequences which differ from those shown in the figures. differentiate sequences by deletion (s), insertion (s), exchange (s) and / or other modifications known in the art or comprise a fragment of the original nucleic acid molecule, the protein or peptide encoded by these DNA sequences still has the above-mentioned properties. It is preferred that the variants still have a homology of at least 80%, preferably at least 90% and very preferably 95%. Functional equivalents, derivatives and precursors (bioprecursors) are therefore included.
  • Derivatives are, for example, mutation derivatives (generated by, for example, deletions or insertions), fusions, allele variants, muteins and splice variants.
  • Methods for generating the above changes in the nucleic acid sequence are known to the person skilled in the art and are described in standard works in molecular biology, for example in Sambrook et al., Supra. The person skilled in the art is also able to determine whether a protein encoded by a nucleic acid sequence modified in this way still has the properties mentioned above.
  • Preferred fragments are the sequences highlighted by underlining in FIGS. 1, 2 and 3.
  • the present invention relates to the use of a DNA sequence which encodes a protein which comprises the amino acid sequence of FIG. 1, 2 or 3 or parts thereof, the protein having the biological activity defined above and can be used to diagnose and treat injuries and tumors of the nervous system.
  • the parts of the sequences are preferably the fragments highlighted in the figures by underlining.
  • vectors or expression vectors containing these DNA sequences can also be used according to the invention.
  • vector refers to a plasmid (eg pUC18, pBR322, pBlueScript), a virus or another suitable vehicle.
  • the DNA molecule in the vector is functionally linked to regulatory elements that express it in prokaryotic or allow eukaryotic host cells.
  • regulatory elements for example a promoter
  • such vectors typically contain an origin of replication and specific genes which allow the phenotypic selection of a transformed host cell.
  • the regulatory elements for expression in prokaryotes for example E.
  • coli include the lac, trp promoter or T7 promoter, and for expression in eukaryotes the AOX1 or GAL1 promoter in yeast, and the CMV, SV40 , RVS-40 promoter, CMV or SV40 enhancer for expression in animal cells. Further examples of suitable promoters are the metallothionein I and the polyhedrin promoter.
  • the vector contains the promoter of the human T gene or an orthologist of the T gene.
  • Suitable expression vectors for E. coli include, for example, pGEMEX, pUC derivatives, pGEX-2T, pET3b and pQE-8, the latter being preferred.
  • Vectors suitable for expression in yeast include pY100 and Ycpadl, pMSXND, pKCR, pEFBOS, cDM8 and pCEV4 for expression in mammalian cells.
  • the expression vectors according to the invention also include vectors derived from baculovirus for expression in insect cells, for example pAcSGHisNT-A.
  • General methods known in the art can be used to construct expression vectors containing the DNA sequences to be used according to the invention and suitable control sequences. These methods include, for example, in vitro recombination techniques, synthetic methods and in vivo recombination methods, as are described, for example, in Sambrook et al., Supra.
  • the DNA sequences to be used according to the invention can also be inserted in connection with a DNA coding for another protein or peptide, so that the DNA sequences can be expressed, for example, in the form of a fusion protein.
  • These other DNAs are preferred reporter sequences which encode a reporter molecule which comprises a detectable protein, for example a dye, an antibiotic resistance, ⁇ -galactosidase or a substance which can be detected by spectroscopic hotometric, spectrofluorometric, luminescent or radioactive assays.
  • the DNA sequences inserted into a vector can be brought into host cells become.
  • host cells include bacteria (for example the E. coli strains HB101, DH1, x1776, JM101, JM109, BL21 and SG13009), fungi, for example yeasts, preferably S. cerevisiae, plant cells, insect cells, preferably sf9 cells, and animal cells, preferably vertebrate or mammalian cells.
  • Preferred mammalian cells are CHO, VERO, BHK, HeLa, COS, MDCK, 293 and WI38 cells. Methods for transforming these host cells, for phenotypically selecting transformants, and for expressing the DNA molecules using the vectors described above are known in the art.
  • the proteins to be used according to the invention preferably have the amino acid sequences shown in FIGS. 1, 2 or 3 or represent fusions, fragments, derivatives or precursors (bioprecursors) thereof, the properties mentioned above being retained in the sense of functional equivalents stay.
  • Derivatives are to be understood in particular as those modified proteins or peptides that differ from the sequences shown in the figures by conservative amino acid exchanges or contain non-conservative amino acid exchanges that do not significantly change the function of the T proteins.
  • Preferred fragments are the sequences highlighted by underlining in FIGS. 1, 2 or 3.
  • antibodies against the proteins described above or against fragments thereof, in particular against the sequences underlined in FIGS. 1, 2 or 3, can also be used instead of the above-described DNA molecules or proteins.
  • These antibodies can be monoclonal, polyclonal or synthetic antibodies or fragments thereof.
  • fragment means all parts of the monoclonal antibody (for example Fab, Fv or “single chain Fv” fragments) which have the same epitope specificity as the complete antibody. The production of such fragments is known to the person skilled in the art.
  • the antibodies are preferably monoclonal antibodies.
  • the antibodies can be prepared according to standard procedures the protein encoded by the DNA sequences or a synthetic fragment thereof serving as an immunogen.
  • Methods for obtaining monoclonal antibodies include, for example, as a first step the production of polyclonal antibodies using the proteins according to the invention or fragments thereof (for example synthetic peptides) as immunogen for immunizing suitable animals, for example rabbits or chickens, and the production of the polyclonal Antibodies from the serum or egg yolk. Then, for example, Zeil hybrids are produced and cloned from antibody-producing cells and bone marrow tumor cells. A clone is then selected which produces an antibody which is specific for the antigen used. This antibody is then made. Examples of cells that produce antibodies are spleen cells, lymph node cells, B-lymphocytes, etc.
  • mice examples of animals that can be immunized for this purpose are mice, rats, horses, goats and rabbits.
  • the myeloma cells can be obtained from mice, rats, humans or other sources.
  • Cell fusion can be carried out, for example, by the well-known Köhler and Milstein method.
  • the hybridomas obtained by cell fusion are screened by means of the antigen by the enzyme-antibody method or by a similar method. For example, clones are obtained using the limit dilution method.
  • the clones obtained are, for example, implanted intraperitoneally in BALB / c mice, the ascites are removed from the mouse after 10 to 14 days, and the monoclonal antibody is purified by known methods (for example ammonium sulfate fractionation, PEG fractionation, ion exchange chromatography, gel chromatography or affinity chromatography).
  • the monoclonal antibody mentioned is an antibody derived from an animal (for example a mouse), a humanized antibody or a chimeric antibody or a fragment thereof. Chimeric, human antibody-like or humanized antibodies have a reduced potential antigenicity, but their affinity for the target is not reduced.
  • Humanized immunoglobulins have variable scaffold areas, which essentially come from a human immunoglobulin (with the name acceptor immunoglobulin) and the complementarity of the determining areas, which essentially come from a non-human immunoglobulin (eg from the mouse) (with the name donor immunoglobulin).
  • the constant region (s), if any, also originate essentially from a human immunoglobulin.
  • humanized (as well as human) antibodies offer a number of advantages over antibodies from mice or other species: (a) the human immune system should not recognize the backbone or constant region of the humanized antibody as foreign and therefore should Antibody response against such an injected antibody is lower than against a completely foreign mouse antibody or a partially foreign chimeric antibody; (b) since the effector area of the humanized antibody is human, it is likely to interact better with other parts of the human immune system, and (c) injected humanized antibodies have a half-life that is essentially equivalent to that of naturally occurring human antibodies, which it is allows smaller and less frequent doses to be administered compared to antibodies from other species.
  • the antibodies can be used, for example, for the immunoprecipitation of the proteins discussed above in the context of the differential diagnosis and therapy of tumors of the nervous system.
  • the antibodies it is possible to examine sections or smears of tumors or other patient material and to determine whether there are protein isoforms of the T protein family that are specific for tumors or injuries. Furthermore, it is also possible to identify protein isoforms that are of prognostic importance for the treatment of patients.
  • the invention enables the differential diagnosis and treatment of cancer, including tumors of the nervous system, such as neuroblastoma, astrocytoma, glioblastoma, medulloblastoma.
  • This diagnosis can be made not only postnatally, but already prenatally.
  • Probes or primers can be determined in mammals, in particular humans, whether they contain a gene which encodes and / or expresses the protein according to the invention or whether this gene leads to a mutated form of the protein which is no longer biologically active.
  • the person skilled in the art can carry out customary methods, such as reverse transcription, PCR, LCR, hybridization and sequencing.
  • the antibodies according to the invention are also suitable for diagnostics, ie for example for the detection of the presence and / or the concentration of the protein according to the invention, a shortened or extended form of the protein etc. in a sample.
  • the antibodies can be bound, for example, in liquid phase immunoassays or to a solid support.
  • the antibodies can be labeled in different ways. Suitable markers and labeling methods are known in the art. Examples of immunoassays are ELISA and RIA.
  • the differentially spliced exon sequences and the protein isoform-specific amino acid sequences encoded therein can also be used to develop new methods and drugs.
  • the protein isoform-specific amino acid sequences are used as binding partners for other proteins or substances in general (chemicals, substance libraries) in order to identify molecules or other proteins which bind to the protein isoform-specific amino acid sequences.
  • This method enables new molecules or proteins to be found that specifically block or enhance the action of individual protein isoforms. The new molecules found can then also influence other proteins that start elsewhere in the signal cascade.
  • Injuries to the nervous system include, for example, traumatic brain injuries or paraplegia.
  • a diagnostic method for the detection of a disturbed expression of the protein according to the invention or for the detection of a modified form of this protein (splicing variant) takes place, in which brings a sample into contact with the DNA or protein sequences or the antibody or fragment thereof and then, for example, directly or indirectly determines whether the concentration of the protein and / or its amino acid sequence differs in comparison to a protein obtained from a healthy patient.
  • the present invention also allows therapeutic measures to be performed on the disorders discussed above, i.e.
  • the DNA sequences, proteins and antibodies according to the invention described above can also be used for the production of a medicament, for example for controlling the expression of the protein according to the invention or for exchanging a mutated form of the gene for a functional form and thus also for the production of a medicament for prevention or the treatment of tumor diseases of the nervous system.
  • the protein according to the invention can be introduced into mammals, in particular humans, by customary measures.
  • BSA bovine serum albumin
  • the therapy according to the invention is carried out with a medicament which contains the DNA sequences described above, the expression vector, the protein or the antibody or fragments thereof.
  • This drug may also contain a pharmaceutically acceptable carrier.
  • Suitable carriers and the formulation of such medicaments are known to the person skilled in the art. Suitable carriers include, for example, phosphate-buffered saline solutions, water, emulsions, for example oil / water emulsions, wetting agents, sterile solutions, etc.
  • the medicaments can be administered orally or parenterally. Methods for parenteral administration include topical, intra-arterial, intramuscular, subcutaneous, intramedullary, intrathecal, intravenous, intravenous, intraperitoneal, or intranasal. The appropriate dosage is determined by the attending physician and depends on various factors, for example the age, gender, weight of the patient, the stage of the disease, the type of administration, etc.
  • the nucleic acids described above are preferably inserted into a vector suitable for gene therapy and introduced into the cells, for example under the control of a tissue-specific vector.
  • the vector containing the nucleic acids described above is a virus, for example an adenovirus, vaccinia virus or adenovirus.
  • Retroviruses are particularly preferred. Examples of suitable retroviruses are MoMuLV, HaMuSV, MuMTV, RSV or GaLV.
  • the nucleic acids according to the invention can also be transported to the target cells in the form of colloidal dispersions. These include, for example, liposomes or lipoplexes (Mannino et al., Biotechniques 6 (1988), 682).
  • a diagnostic kit for carrying out the diagnostic method described above which contains at least one of the above-described DNA sequences, the protein or the above-described antibody or fragments thereof.
  • the DNA sequence, protein sequence or the antibody or fragments thereof can be immobilized.
  • Sequences of the T genes can be applied to nylon membranes or glass supports and hybridized with samples (DNA, cDNA or RNA) from tumors and associated normal tissues, or sick and associated healthy tissues. This enables the (fully automated) detection of the expression of these genes.
  • the sequences used for this can be, for example, the entire cDNA sequence or short sequence sections, for example 10-15 bp oligomers.
  • the therapy including cancer therapy, can then be specifically selected or adapted according to the individual situation of the patient.
  • Hybridization with the T genes makes it possible to express the individual T genes and T gene partial sequences. to determine zen. This makes it possible to carry out a very quick diagnosis and to adapt a therapy to the molecular genetic peculiarities. This is associated with a significantly increased therapy or healing rate.
  • the isolation and characterization of the above sequences, in particular the different splice variants, allow the establishment of an animal model, which is very valuable for the further study of injuries to the nervous system and cancer at the molecular level.
  • a non-human mammal is also being developed for diagnostic purposes, the T1 gene or the T2 or T3 gene of which has been altered, e.g. by inserting a heterologous sequence, in particular a selection marker sequence.
  • non-human mammal includes any mammal whose T gene, or T2 or T3 gene, may be altered. Examples of such mammals are mouse, rat, rabbit, horse, cattle, sheep, goat, monkey, pig, dog and cat, with mouse being preferred.
  • T gene or T2 or T3 gene that has been changed means that the gene which occurs naturally in the non-human mammal is modified by standard methods by means of standard methods to change the gene structure or the gene sequence. This can be achieved, inter alia, by introducing a deletion of approximately 1-2 kb, in the place of which a heterologous sequence, for example a construct for mediating antibiotic resistance (for example a “neo-cassette”), is introduced. Furthermore, heterologous sequences can be introduced into the T gene, which allow time and tissue-specific deletions to be carried out in vivo. Furthermore, heterologous sequences can be introduced into the T gene, which make it possible to follow the expression of the T gene in vivo.
  • the change can be carried out as described below. For example, you can delete the underlined exon sequences or change them so that the gene is spliced in a different way than usual.
  • a sequence can be inserted into this intron which is recognized as an exon and which is spliced to the exons of the T gene located in front of it.
  • This inserted sequence can be, for example, an exon that encodes the EGFP protein (Enhanced Green Fluorescent Protein). This turns the original T gene into a fusion protein that contains the EGFP protein.
  • a mouse can preferably be generated which allows the expression of the T gene to be monitored in vivo.
  • the inserted sequence can be designed in the end (eg polyA signal, splice signals, etc.) such that no further exons of the T gene are spliced to the inserted exon or the spliced exons are no longer translated. This results in a deletion of the mouse T protein at the C-terminal end or a premature termination of the reading frame and an (at least partial) inactivation of the protein function of the mouse T gene can be achieved.
  • sequences can also be inserted as current exon sequences which result in an mRNA sequence in which this new mRNA sequence is located at the 3 'end.
  • Suitable sequences can then be used to change the stability of the mRNA or to change its location in the cell.
  • the the associated phenotype of the mice modified in this way can then provide important conclusions about the function of the T gene. These mice can then also be used to find new active substances that compensate for the loss of function of the T gene.
  • Cells from the above non-human mammal can also be obtained. These cells can be in any form, e.g. in a primary or long-term culture.
  • a non-human mammal can be provided by conventional methods.
  • a method is favorable which comprises the following steps:
  • step (c) transforming the embryonic stem cells from step (b) with the DNA fragment from step (a), the T gene in the embryonic stem cells being changed by homologous recombination with the DNA fragment from (a),
  • step (d) culturing the cells of step (c),
  • step (e) selection of the cultured cells from step (d) for the presence of the heterologous sequence, in particular the selectable marker,
  • step (f) generating chimeric non-human mammals from the cells of step (e) by injecting these cells into mammalian blastocysts (preferably mouse Blastocysts), transfer of the blastocysts into pseudo-pregnant female mammals (preferably mouse) and analysis of the progeny obtained for a change in the T gene.
  • mammalian blastocysts preferably mouse Blastocysts
  • pseudo-pregnant female mammals preferably mouse
  • step (c) the mechanism of homologous recombination (see R.M. Torres, R. kuhn, Laboratory Protocols for Conditional Gene Targeting, Oxford University Press, 1997) is used to transfect embryonic stem cells.
  • the homologous recombination between the DNA sequences present in a chromosome and new, added cloned DNA sequences enables the insertion of a cloned gene into the genome of a living cell instead of the original gene.
  • embryonic germ cells can be used to obtain via chimeras animals that are homozygous for the desired gene or the desired gene part or the desired mutation.
  • embryonic stem cells refers to any embryonic stem cells from a non-human mammal that are suitable for mutating the T gene.
  • the embryonic stem cells are preferably from the mouse, in particular the cells E14 / 1 or 129 / SV.
  • vector encompasses any vector which, by recombination with the DNA of embryonic stem cells, enables a change in the T1, T2 or T3 gene.
  • the vector preferably has a marker which can be used to select for existing stem cells in which the desired recombination has taken place.
  • a marker is e.g. the loxP / tk neo-cassette, which can be removed from the genome again using the Cre / loxP system.
  • the present invention provides a non-human mammal whose T1, T2 or T3 gene is altered. This change can be a switching off of the gene expression regulating function. With such a mammal or cells from them, the gene expression-controlling function of the T protein can be examined selectively. It is also possible to find substances, drugs and therapeutic approaches that can be used to selectively influence the controlling function.
  • the present invention therefore provides a basis for acting on a wide variety of diseases. Such diseases are, for example, restrictions on the CNS functions due to injury or the induction of cancer due to errors in the control of cell proliferation.
  • Figure 1 human cDNA sequence (gene T1) and deduced amino acid sequence underlined sequences: exon
  • Figure 2 human cDNA sequence (gene T2) and deduced amino acid sequence underlined sequences: exon
  • Figure 3 human cDNA sequence (gene T3) and deduced amino acid sequence underlined sequences: exon
  • cDNA clone pL70 (DSM13270); represents essential parts of the T3 gene.
  • Fig. 1 The sequence shown in Fig. 1 comes from the clones JFC277 (DSM 12371), JFC405 (DSM 12372) and JFC-BN27 (DSM 12659) and JFC-BN20 (DSM 12698).
  • the first strand cDNA was synthesized using 250 ng hexanucleotides (from Pharmacia) per 1 ⁇ g total RNA.
  • the PCR reactions were carried out with gene-specific primers and first-strand cDNA. The following primers and combinations of primers were used:
  • POMFIL 1-1 CTCCTTGTCTGGACTGACCACAG
  • POMFIL 1-2 GCCTTCAGCATTTCAATGGTTTCTC
  • POMFIL 2-1 TCAGAGTCTCAAGGCAGTGG
  • POMFIL 2-2 GCCAGGTAGGTTTTCCCAG
  • POMFIL 3-1 CAGTGCAGAATGTCCTGGATCTC
  • POMFIL 3-2 GATGAATCATCACAGCTCTCAGG
  • TFR Transferin Receptor
  • TFR1 TCTTTGGACATGCTCATCTGGGG
  • TFR2 ACAGGTGACCCTTACACACCTGG
  • TFR4 CAAAGTCTCCAGCACTCCAACTG
  • POMFIL primers 300 ng were used per 50 ⁇ l PCR reaction, whereas 38 ng were used for the transferin receptor primers.
  • Duplex PCRs were performed with primers that amplified an independent control. 4A above: POMFIL1 and as a control TFR and POMFIL2 and POMFIL3 as a mutual control. The same applies to Fig. 4B.
  • T1 and T2 are expressed in glioblastoma cell lines H4 and A172, whereas expression of T3 is absent. All members of the T gene family are expressed in the four of seven glioblastoma cell lines tested (U118MG, U373MG, U87MG and HS683). No expression of the T gene family was detectable in the U343MG glioblastoma cell line.
  • the medulloblastoma cellemia DAOY showed reduced T1 and T2 expression, while T3 expression was absent.
  • the rabbit's serum is tested in an immunoblot.
  • the peptide used for the immunization is subjected to SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose filter (cf. Khyse-Andersen, J., J. Biochem. Biophys. Meth. 10, (1984), 203-209).
  • Western blot analysis was performed as described in Bock, C.-T., et al., Virus Genes 8, (1994), 215-229.
  • the nitrocellulose filter is incubated for one hour at 37 ° C. with a first antibody. This antibody is rabbit serum (1: 10000 in PBS). After several washing steps with PBS, the nitrocellulose filter is incubated with a second antibody.
  • This antibody is a goat anti-rabbit IgG antibody (Dianova) (1: 5000) coupled with alkaline phosphatase in PBS. After 30 minutes of incubation at 37 ° C, there are several washing steps with PBS and then the alkaline phosphatase detection reaction with developer solution (36 ⁇ M 5 'bromo-4-chloro-3-indolylphosphate, 400 ⁇ M nitroblue tetrazolium, 100mM Tris-HCl, pH 9.5, 100 mM NaCI, 5 mM MgCI 2 ) at room temperature until bands become visible.
  • developer solution 36 ⁇ M 5 'bromo-4-chloro-3-indolylphosphate, 400 ⁇ M nitroblue tetrazolium, 100mM Tris-HCl, pH 9.5, 100 mM NaCI, 5 mM MgCI 2
  • Antibodies are extracted from egg yolk and tested in a Western blot. Polyclonal antibodies according to the invention are detected.
  • T gene family has shown that, for example, previously indistinguishable brain tumors can be distinguished by recording the expression of the three T genes in different brain tumor subtypes. This represents an excellent one Possibility of how a molecular genetic classification of tumors can be carried out.
  • the expression of these genes is recorded using PCR. It is particularly important here that each of these three genes not only encodes a protein, but that many splicing variants lead to different protein isoforms. Not just the expression of the individual T-
  • Genes, but also the individual protein isoforms, can thus be used as tumor-relevant markers. This makes it e.g. It is possible to classify previously indistinguishable forms of brain tumors from molecular genetics into subclasses. This opens up the possibility of optimally adapting the therapy of these tumors to the molecular genetic conditions. This makes it possible to
  • the expression of any member of the T gene family can be recorded.
  • the tumors can be classified by determining the combinations and the level of expression of the individual T genes. In this way, previously undistinguishable brain tumors can be distinguished on a molecular-genetic basis.
  • the expression of the differentially spliced exons which for
  • the different splicing options allow eight different protein isoforms for each individual T protein, since there are three different T genes, 512 possible protein isoform combinations result from this. This means that without considering the quantitative expression level, each cell has a large variety of possibilities to assemble the T proteins and isoforms. The procedure described above makes it possible to determine which of these protein isoform combinations is present. Furthermore, it is also possible to convert the individual mRNAs or protein isoform quantify quantities. The qualitative and quantitative determination of the protein isoform combinations makes it possible to classify the diseases at the mRNA level and protein level.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'utilisation de protéines T et des séquences d'acide nucléique qui les codent et d'anticorps agissant à l'encontre des protéines T pour effectuer une caractérisation et une thérapie différentielle de lésions et de tumeurs du système nerveux.
PCT/DE2001/003392 2000-08-30 2001-08-29 Utilisation de proteines t pour une caracterisation et une therapie differentielles de lesions et de tumeurs du systeme nerveux Ceased WO2002017947A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10042609.3 2000-08-30
DE2000142609 DE10042609A1 (de) 2000-08-30 2000-08-30 Verwendung von T-Proteinen zur differentiellen Charakterisierung und Therapie von Verletzungen und Tumoren des Nervensystems

Publications (2)

Publication Number Publication Date
WO2002017947A2 true WO2002017947A2 (fr) 2002-03-07
WO2002017947A3 WO2002017947A3 (fr) 2003-03-20

Family

ID=7654320

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2001/003392 Ceased WO2002017947A2 (fr) 2000-08-30 2001-08-29 Utilisation de proteines t pour une caracterisation et une therapie differentielles de lesions et de tumeurs du systeme nerveux

Country Status (2)

Country Link
DE (1) DE10042609A1 (fr)
WO (1) WO2002017947A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003085134A3 (fr) * 2002-04-05 2004-04-15 Japan President Univ Tokyo Methodes de diagnostic et de traitement du cancer colorectal
EP3816934A1 (fr) 2019-11-04 2021-05-05 Nathan Vinçon Procédé et système informatique pour l'étiquetage d'une image de cellules d'un patient
WO2024215528A1 (fr) 2023-04-13 2024-10-17 Ventana Medical Systems, Inc. Dosage de prolifération pour des tumeurs solides fixes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510944D0 (en) * 1995-05-31 1995-07-26 Bogaert Thierry Assays and processes for the identification of compounds which control cell behaviour,the compounds identified and their use in the control of cell behaviour
GB9625283D0 (en) * 1996-12-04 1997-01-22 Janssen Pharmaceutica Nv Vertebrate homologues of unc-53 protein of c.elegans or functional eqivalents thereof and cdna sequences coding for said homologue
GB9811962D0 (en) * 1998-06-03 1998-07-29 Janssen Pharmaceutica Nv Vertebrate homologue of UNC-53 protein of C.elegans
DE19908423A1 (de) * 1999-02-26 2000-08-31 Deutsches Krebsforsch An der Entwicklung des ZNS beteiligtes Protein (TP)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003085134A3 (fr) * 2002-04-05 2004-04-15 Japan President Univ Tokyo Methodes de diagnostic et de traitement du cancer colorectal
EP3816934A1 (fr) 2019-11-04 2021-05-05 Nathan Vinçon Procédé et système informatique pour l'étiquetage d'une image de cellules d'un patient
WO2021089589A1 (fr) 2019-11-04 2021-05-14 Sapiens Biosciences Procédé et système informatisé pour marquer une image de cellules d'un patient
US12293514B2 (en) 2019-11-04 2025-05-06 Ummon Healthtech Method of, and computerized system for labeling an image of cells of a patient
WO2024215528A1 (fr) 2023-04-13 2024-10-17 Ventana Medical Systems, Inc. Dosage de prolifération pour des tumeurs solides fixes

Also Published As

Publication number Publication date
DE10042609A1 (de) 2002-03-28
WO2002017947A3 (fr) 2003-03-20

Similar Documents

Publication Publication Date Title
DE69430130T2 (de) Polypeptide von der semaphorin-genfamilie
DE69034171T2 (de) Rekombinanter Proteaseinhibitor des Alzheimer-Amyloid-Proteins
DE60118382T2 (de) Protoonkogen aus menschlichem Zervikalkarzinom 2 und darin kodiertes Protein
DE69434431T2 (de) Methoden zur behandlung von muskelerkrankungen und muskelstörungen
DE69233468T3 (de) Prüfung und modell für alzheimers-krankheit
DE69936315T2 (de) Fragmente des wachstumsfaktors für bindegewebe (ctgf) und verfahren und anwendungen davon
DE3752253T2 (de) Rekombiniertes Alzheimer Amyloid-Protein.
DE68928491T2 (de) Erzeugnisse und verfahren zur regelung der suppression von neoplastischen phenotypen
DE69636720T2 (de) Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung
DE69302234T2 (de) Menschliches Prohibitin und Prohibitin kodierende DNS
DE69924120T2 (de) Für ataxin-2-bindende proteine kodierende nukleinsäure, damit verwandten produkten und verfahren zur deren anwendung
EP0805204B1 (fr) Protéine récepteur spécifique de l'épididyme et son utilisation
AT410672B (de) Nucleinsäure, die einen nervengewebe-natriumkanal kodiert
WO2002017947A2 (fr) Utilisation de proteines t pour une caracterisation et une therapie differentielles de lesions et de tumeurs du systeme nerveux
DE69734890T2 (de) Rdgb-proteine
EP1237910B1 (fr) Proteine mtr1 apparentee aux proteines trp et sequence adn codant pour celle-ci
DE69728436T2 (de) Leptin-protein aus schwein, dafür kodierende nukleinsäuren und verwendungen davon
EP1165607A2 (fr) Proteine (tp) impliquee dans le developpement du systeme nerveux central
DE69616288T2 (de) Nukleotid sequenzen und daraus abgleitete aminosäuresequenzen vom tumorgen int 6
DE69929876T2 (de) Für hm1.24 antigen kodierendes gen und dessen promotor
DE69832447T2 (de) Gen kodierend für Afadin-1
DE10009119A1 (de) Vertebraten Globin
DE10001377A1 (de) bHLH-Transkriptionsfaktor ASCL3 und diesen enthaltendes Arzneimittel
DE19816186A1 (de) GDNF-kodierende DNA, Teile davon und GDNF-Varianten
WO1993013205A1 (fr) Gene regulateur associe au neuroblastome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP